Haw ParHAWPF 93 EBIT per Share is $0.99 as of Dec. 2025. GuruFocus rates HAWPF with a GF Score™ of 93/100 and a GF Value™ of $8.90. The stock has 3 warning signs investors should review. Among 811 Drug Manufacturers companies, Haw Par ranks better than 61.53% on this metric.
Haw Par's EBIT per Share for the
six
months ended in Dec. 2025 was $0.46.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.99.
During the past 12 months, the average EBIT per Share Growth Rate of Haw Par was 5.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 15.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 37.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Haw Par's EBIT per Share or its related term are showing as below:
HAWPF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -42.2 Med: 8.55 Max: 66.2
Current: 15.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Haw Par was 66.20% per year. The lowest was -42.20% per year. And the median was 8.55% per year.
HAWPF's 3-Year EBIT Growth Rate is ranked better than 61.53% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs HAWPF: 15.60
Haw Par's EBIT for the
six
months ended in Dec. 2025 was $101.0 Mil.
Haw Par (OTCPK:HAWPF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Haw Par EBIT per Share Related Terms
Haw Par EBIT per Share Historical Data
* Premium members only.
The historical data trend for Haw Par's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a EBIT per Share of $0.99 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Haw Par and its competitors. According to the industry distribution chart, Haw Par ranks #312 out of 811 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is Haw Par's EBIT per Share too high?
Haw Par's current EBIT per Share is $0.99. The Drug Manufacturers industry median EBIT per Share is 7.80. Haw Par's value of $0.99 is 87.3% below this industry median. Based on the distribution chart, Haw Par ranks #312 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Haw Par has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #312 out of 811 companies for EBIT per Share. This puts Haw Par in the upper half of its industry. The industry median EBIT per Share is 7.80. Haw Par's value of $0.99 is 87.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current EBIT per Share of $0.99 is 87.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current EBIT per Share is $0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current EBIT per Share of $0.99. The stock's GF Value™ is $8.90, compared to a current price of $12.00 — trading 34.8% above its estimated fair value. The current EBIT per Share is $0.99 and 87.3% below the Drug Manufacturers industry median of 7.80. Haw Par's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Haw Par (HAWPF), the current EBIT per Share is $0.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 34.8% above its estimated GF Value™ of $8.90.
Key valuation signals for HAWPF:
EBIT per Share: $0.99
GF Value™: $8.90 vs. price of $12.00 (34.8% above fair value)
Industry Position: 87.3% below the Drug Manufacturers median (#312 of 811)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
93GF Score
Get the complete analysis for HAWPF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
